Catheter Precision, Inc.
Compare this stock
VTAK Stock Report Card
$
65%
Performance
Score:
10/100
VTAK returned -27.27% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
75/100
4 analysts offer 12-month price targets for VTAK. Together, they have an average target of 0, the most optimistic target put VTAK at 0 within 12-months and the most pessimistic has VTAK at 0.
Earnings
Score:
100/100
VTAK has missed earnings 0 times in the last 20 quarters.
Volatility
Score:
48/100
VTAK has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Catheter Precision, Inc. Summary
Healthcare
Medical - Devices
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
VTAK scored highly on our reportcard. Here are some similar companies and how they performed.
